FDA
-
-
-
-
-
-
-
Kazia Therapeutics names Dr. Sudha Rao as chief scientific officer
-
-
-
-
-
-
-
Kazia Therapeutics reports responses in breast cancer trial
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Kazia Therapeutics (KZIA)
-
-
-
-
-
-
-
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
-
-
-
-
-
-
-
Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
-
-
-
-
-
-
-
Kazia Therapeutics announces the launch of a groundbreaking trial with paxalisib in combination with immunotherapy in women with advanced breast cancer
-
-
-
-
-
-
-
Kazia Therapeutics (KZIA) Granted Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib
-
328,149 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

